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Background: Open surgery with resection and colostomy (Hartmann’s procedure) has been the standard
treatment for perforated diverticulitis with purulent peritonitis. In recent years laparoscopic lavage has
emerged as an alternative, with potential benefits for patients with purulent peritonitis, Hinchey grade
III. The aim of this study was to compare laparoscopic lavage and Hartmann’s procedure with health
economic evaluation within the framework of the DILALA (DIverticulitis – LAparoscopic LAvage versus
resection (Hartmann’s procedure) for acute diverticulitis with peritonitis) trial.
Methods: Clinical effectiveness and resource use were derived from theDILALA trial and unit costs from
Swedish sources. Costs were analysed from the perspective of the healthcare sector. The study period was
divided into short-term analysis (base-case A), within 12 months, and long-term analysis (base-case B),
from inclusion in the trial throughout the patient’s expected life.
Results: The study included 43 patients who underwent laparoscopic lavage and 40 who had Hartmann’s
procedure in Denmark and Sweden during 2010–2014. In base-case A, the difference in mean cost per
patient between laparoscopic lavage and Hartmann’s procedure was €–8983 (95 per cent c.i. –16 232 to
–1735). The mean(s.d.) costs per patient in base-case B were €25 703(27 544) and €45498(38 928) for
laparoscopic lavage and Hartmann’s procedure respectively, resulting in a difference of €–19 794 (95 per
cent c.i. –34 657 to –4931). The results were robust as demonstrated in sensitivity analyses.
Conclusion: The significant cost reduction in this study, together with results of safety and efficacy from
RCTs, support the routine use of laparoscopic lavage as treatment for complicated diverticulitis with
purulent peritonitis.
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Introduction
Diverticulosis is a common condition in theWestern world
and increases with age. Some 15–25 per cent of patients
with diverticulosis also develop an inflammatory condition,
diverticulitis1. Diverticulitis can be divided into uncompli-
cated and complicated disease. In the 1970s, Hinchey and
colleagues2 suggested that the more complicated condition
should be classified using intraoperative findings. Hinchey
grade III indicates perforated colon with purulent peritoni-
tis and grade IV represents perforated colon with faecal
leakage into the abdomen.
For Hinchey grade III and IV diverticulitis the standard
treatment has been emergency surgery, commonly open
surgery with resection of the diseased bowel segment3. An
end colostomy is constructed and the rectal stump is over-
sewn or stapled (Hartmann’s procedure)3,4. The stoma can
be reversed in a future operation, although with associated
risk of morbidity and mortality5. Another less common
option is colonic resection with primary anastomosis with
or without a diverting ileostomy4. Recent reports6,7 have
shown that an alternative, comprising laparoscopy, lavage
and drainage without colonic resection or stoma, exists for
Hinchey grade III.
© 2016 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS 2016; 103: 1539–1547
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Four RCTs have been initiated comparing open
resection with laparoscopic lavage, and three have
reported results8–11: DILALA, SCANDIV (Scandinavian
Diverticulitis trial) and LOLA (treatment arm in
Laparoscopic Peritoneal Lavage or Resection for General
Peritonitis for Perforated Diverticulitis (LADIES) trial).
The primary composite endpoint of LOLA, major mor-
bidity and mortality within 1 year after index surgery, was
reached in 67 per cent in the laparoscopic lavage group
and 60 per cent in the sigmoid resection group10. The
primary outcome in the SCANDIV trial was severe post-
operative complications at 90 days, which affected 31 per
cent of patients in the lavage group and 26 per cent in the
colonic resection group9. Neither of these trials reported
statistically significant differences in primary endpoints.
The primary endpoint of DILALA was percentage of
patients undergoing one or more reoperation within 12
months: 28 per cent in the laparoscopic lavage group and
63 per cent in the Hartmann’s procedure group, a signif-
icant difference (P= 0⋅004)11. Furthermore, duration of
surgery, length of hospital stay, time in the recovery room
and number of transfusions differed significantly between
the groups in favour of laparoscopic lavage. There were
no significant differences in secondary outcomes such
as complications, mortality, or health-related quality of
life measured with EQ-5D™ (EuroQol Group, Rotter-
dam, The Netherlands) and Short Form 36 (SF-36®;
QualityMetric, Lincoln, Rhode Island, USA)8,11.
However, economic evaluations comparing laparoscopic
lavage and colonic resection for complicated diverticulitis
are still lacking. One RCT12 reported the costs associated
with Hartmann’s procedure and resection with primary
anastomosis in patients with complicated diverticulitis, and
found no significant difference with regard to in-hospital
costs for these procedures. The aim of the present study
was to assess the costs of laparoscopic lavage versus Hart-
mann’s procedure and to relate them to clinical effective-
ness in the DILALA trial.
Methods
DILALA trial
DILALA is an RCT comparing the outcomes of laparo-
scopic lavage versus Hartmann’s procedure for perforated
diverticulitis with purulent peritonitis (Hinchey grade
III)13. The study was conducted at nine centres in Sweden
and Denmark from February 2010 to February 2014.
Inclusion criteria comprised radiological examination
showing intra-abdominal fluid or gas, and the decision
to perform surgery. Each patient gave informed consent
before surgery. The procedure started with a diagnostic
laparoscopy; if diverticulitis Hinchey grade III was found,
the patient was randomized to laparoscopic lavage or
Hartmann’s procedure. Clinical information was collected
for the operative and postoperative phases, as well as for
follow-up at 6–12 weeks, 6 months and 1 year13. Elective
colonic resection at a later stage was not recommended
as routine in the trial protocol. It was recommended only
if considered necessary as an emergency procedure in the
event of recurrent complicated diverticulitis or to treat
complications after the initial diverticulitis (for example
fistulas or colonic strictures).
The present economic analysis of the DILALA trial is
reported according to the CHEERS guideline, as recom-
mended by the EQUATOR network14.
Health economic methodology
As laparoscopic lavage resulted in significantly fewer reop-
erations than Hartmann’s procedure, superiority in terms
of effectiveness was demonstrated. For the cost analysis,
resource use was recorded in the DILALA trial, from all
centres in Denmark and Sweden. Unit costs were derived
from Swedish sources and subsequently applied to all
patients in the study. All randomized patients were included
and analysis was by intention to treat. The analysis included
two time intervals; one included all costs accumulated
during 12 months in the trial (base-case A) and the other
included all costs from inclusion in the trial throughout the
patient’s expected lifetime (base-case B). The costs were
analysed from the perspective of the healthcare sector.
Data collection
Resource use was collected at patient level in the DILALA
trial. For the present analysis some resource use items
were aggregated into meaningful measures. The principle
of ‘gross-costing’ was applied for predictable combinations
of specific resource use items, expected to be driven in
some predetermined way by, for example, hospital procure-
ment decisions rather than differences associated with the
surgical interventions studied15.
Resource use
Basic laparoscopic equipment was the same regardless of
hospital; therefore, a set of equipment was identified at
Sahlgrenska University Hospital, Sweden. The number of
laparoscopic procedures from 2013 and 2014 was extracted
from an administrative database at the same hospital.
None of the procedures was robot-assisted. The total
cost of equipment was divided by number of laparoscopic
procedures to obtain a cost per laparoscopic operation.
This cost was used for all procedures in the laparoscopic
lavage group.
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 1539–1547
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Surgical instruments needed per surgical technique were:
vessel-sealing instruments, stapling instrument to divide
the colon and close the rectal remnant, suture materials
and laparoscopic ports. The use of disposable instruments
was collected individually and applied in the analysis. Saline
for rinsing of the abdomen was included in this category of
resource use. The decision on available instrument brand
was made at departmental level, and was therefore unre-
lated to type of surgical technique15.
Duration of anaesthesia, time in the recovery room,
number of transfusions, length of hospital stay, frequency
of reoperations and length of hospital stay during read-
mission without reoperation were collected at the patient
level. It was assumed that the exact items of resource use for
the two treatments were the same for duration of anaes-
thesia (except basic laparoscopic equipment and surgical
instruments), time in recovery room, number of transfu-
sions, length of hospital stay, colonoscopies and reopera-
tions. The same assumption was made for stoma reversal
and sigmoidectomy in the base-case B analysis. Therefore,
gross-costing was used for all variables in this section.
In both base-case analyses, a colonoscopy was included
for all patients in the laparoscopic lavage group during
the first year after primary surgery to diagnose cancer if
present. All patients in the Hartmann’s procedure group
who had stoma reversal surgery were also assumed to
undergo preoperative diagnostic colonoscopy. In base-case
B, the cost of colonoscopy was added for all patients who
underwent stoma reversal surgery.
A standard antibiotic treatment per type of infectious
adverse event was assumed to be 3 days of intravenous
piperacillin and tazobactam, and an additional 7 days of oral
metronidazole and cephalosporin. Only infectious adverse
events occurring within 90 days of the index operation were
assumed to relate to the index surgical procedure.
Relatively few patients (5 of 43 in the laparoscopic lavage
group and 5 of 37 in theHartmann’s procedure group) were
admitted to the ICU. Time in the ICU was excluded from
the cost analysis because it was deemed unrelated to the
underlying surgical technique.
Presence of a stoma is expected to lead to a difference in
resource use between the treatments. All patients under-
going Hartmann’s procedure have a colostomy from the
index operation onwards and the stoma was reversed either
during the trial, after the trial, or not at all. Days with a
stoma were calculated. The resource items needed per day
for stoma care were estimated for a typical patient with
a stoma in collaboration with a specialized stoma nurse.
After the 1-year follow-up in the trial, there are patients
who may still have a stoma. Although it is possible to
reverse the colostomy, many studies have concluded that
the colostomy may not be reversed16. This is important
when considering the comparative costs of the procedures
because a stoma will incur costs each year for the duration
of the patient’s expected lifetime. To model the expected
cost for a patient with a stoma after 12 months, a decision
tree with corresponding probabilities and unit costs was
set up17. The events included were stoma reversal later
than 12 months (25 per cent) and non-reversal (75 per
cent), and concurrent events included success (86 per
cent), creation of another stoma owing to failure to reverse
(13 per cent) and death (1 per cent) (Fig. S1, supporting
information). These probabilities were derived from a
population-based study by Salem and colleagues18 on
Hartmann’s procedure and reversal in diverticulitis. The
study included 5420 colostomies performed between 1987
and 2000, and used a Washington State administrative
database. The cost per branch in the decision model was
multiplied by the probability of the event occurring during
a patient’s lifetime, resulting in a total expected cost per
patient added to the base-case B analysis. The mean life
expectancy was calculated for patients with a stoma at 12
months, and was 20 years.
For laparoscopic lavage, the inflamed part of the bowel
was not resected during the index operation. After 12
months some patients may undergo a secondary operation
to resect the affected bowel segment owing to recurrence
(although this is debated) or further complications19,20. As
the last follow-up was at 12months, it was assumed that 25
per cent of the patients who underwent laparoscopic lavage
would later require a resection with primary anastomosis
and the creation of a loop ileostomy (25 per cent) or not (75
per cent) (Fig. S2, supporting information). The ileostomy
was assumed to be reversed after 3 months. These events
were modelled using a decision tree model with cost
weighted by the probability of their occurrence, and the
expected costs were included in the base-case B analysis17.
Probabilities and costs for the decision tree models can
be found in Tables S1 and S2 (supporting information).
Unit costs
The unit costs for basic laparoscopic equipment and surgi-
cal instruments were derived from region Västra Götaland
in Sweden, which procures healthcare goods and services
centrally for a region of approximately 1⋅6 million inhabi-
tants. A full list of instruments and other disposable mate-
rials used in this study and their unit costs can be found
Tables S3 and S4 (supporting information).
The unit costs for duration of anaesthesia, time in
the recovery room, transfusions, length of hospital stay,
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 1539–1547
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Table 1 Baseline characteristics
Laparoscopic
lavage
(n=43)
Hartmann’s
procedure
(n=40)
Age (years)* 64 (50–76) 68 (56–79)
Sex ratio (M : F) 21 : 22 16 : 24
BMI (kg/m2)*† 25⋅6 (24⋅9–27⋅8) 24⋅9 (22⋅5–28⋅2)
ASA fitness grade‡
I: healthy 7 9
II: mild systemic disease 24 13
III: severe systemic disease 9 13
IV: severe life-threatening
systemic disease
0 2
*Values are median (i.q.r.). †Data missing for ten patients in lavage group
and 12 in Hartmann’s group; ‡data missing for three patients in each
group.
colonoscopy and readmissions were collected after inter-
views with an economist at Sahlgrenska University Hos-
pital, Sweden. It was ascertained that the unit cost rep-
resented the actual cost per unit and did not entail the
cost of composite variables in the present study. The cost
per day for stoma material (in both base-case analyses)
and the cost per dose of the antibiotic treatment were
obtained from pharmacy retail prices in Sweden. The unit
cost per type of reoperation (classified using the Nordic
Medico-Statistical Committee (NOMESCO) Classifica-
tion of Surgical Procedures version 1.16) was collected
from the national cost per patient database (Swedish Asso-
ciation of Local Authorities and Regions). Unit costs for
elective readmission and sigmoidectomy (with and without
ileostomy) and stoma reversal used in the two models were
also collected from this source. The unit costs for reop-
erations per NOMESCO code can be found in Table S5
(supporting information).
All costs are expressed in euros (1 Swedish krona= 0⋅11
euros; exchange rate 22 March 2016).
Table 2 Clinical resource use
Laparoscopic
lavage (n=43)
Hartmann’s
procedure (n=40) Source
Basic laparoscopic equipment 43 – Estimated by personnel from
operating ward
Surgical instruments† Actual use Actual use DILALA
Duration of anaesthesia (min)* 129(8) 222(10) DILALA
Transfusions (units)* 0⋅3(0⋅1) 0⋅4(0⋅2) DILALA
Time in recovery room (min)* 383(74) 470(79) DILALA
Length of hospital stay, index surgery (days)* 9(1) 11(1) DILALA
Patients requiring antibiotics (infectious adverse events) 27 18 DILALA
Colonoscopy 40 21 DILALA
Reoperation 15 32 DILALA
Time with stoma (days)* 16(10) 206(21) DILALA
Length of hospital stay, readmission (days)* 5(2) 1(1) DILALA
*Value are mean(s.d.). †Surgical instrument use was determined at the patient level; for exact resource utilization see Table S4 (supporting information).
Statistical analysis
Data on cost and resource use collected alongside clin-
ical trials often exhibit a right-skewed distribution21.
Arithmetic mean costs and 95 per cent percentile confi-
dence intervals (c.i.) in the laparoscopic lavage group and
the Hartmann procedure group were calculated using a
non-parametric bootstrap method22.
Two methods have been recommended as a minimum
requirement to account for censoring, referred to as Lin,
and Bang and Tsiatis23. In the Lin method24, the mean cost
per patient at each time point is weighted by the corre-
sponding probability of survival. In the present cost analy-
sis, the time points consist of follow-up times (6–12 weeks,
6 months and 12 months after surgery). The Bang and
Tsiatis25 method involves weighting the patient-specific
cost by the inverse probability of the patient being observed
(not censored) at the beginning of each follow-up. Results
of both methods are presented as sensitivity analyses.
One-way sensitivity analysis was employed to assess the
impact of variables with considerable influence on the
base-case results. The costs were changed by 30 per cent
for one variable at a time for either laparoscopic lavage or
Hartmann’s procedure.
All analyses were performed in Stata® release 14 (Stata-
Corp, College Station, Texas, USA).
Results
Of 139 enrolled patients undergoing diagnostic
laparoscopy, 83were randomized to laparoscopic lavage (43
patients) or Hartmann’s procedure (40). Baseline clinical
characteristics are presented in Table 1. During the course
of the trial six patients died and three were lost to follow-up
in the laparoscopic lavage group, and six and four respec-
tively in the Hartmann’s procedure group; these patients
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 1539–1547
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Table 3 Unit cost per resource use variable
Unit cost (€) Unit Source
Basic laparoscopic equipment 197 Per laparoscopic lavage Region Västra Götaland, Sweden
Surgical instruments* Cost per item Per laparoscopic lavage and
Hartmann’s procedure
Region Västra Götaland, Sweden
Duration of anaesthesia 25 Per minute Sahlgrenska University Hospital,
Gothenburg, Sweden
Transfusion 137 Per unit Sahlgrenska University Hospital,
Gothenburg, Sweden
Time in recovery room 64 Per hour Sahlgrenska University Hospital,
Gothenburg, Sweden
Length of hospital stay, index operation 720 Per day Sahlgrenska University Hospital,
Gothenburg, Sweden
Antibiotics (infectious adverse events) 99–131 Per antibiotic treatment Pharmacy retail price
Colonoscopy 468 Per examination Sahlgrenska University Hospital,
Gothenburg, Sweden
Reoperation* See Methods Per type of reoperation Swedish Association of Local
Authorities and Regions
Stoma material 8 Per day with ileostomy Pharmacy retail price
13 Per day with colostomy
Length of hospital stay, readmission 720 Per day Sahlgrenska University Hospital,
Gothenburg, Sweden
Expected cost, stoma† 67 236 Per stoma
Expected cost, sigmoid resection† 4282 Per sigmoid resection
*Unit costs of surgical instruments and reoperations are available in Tables S3 and S4 (supporting information). †The expected costs for stoma and
sigmoid resection after cessation of the clinical trial are included in the base-case B analysis. These costs are added only for eligible patients. For detailed
calculations see Tables S1–S3 (supporting information).
were censored. The resource use and corresponding unit
costs are shown in Tables 2 and 3 respectively.
The mean cost per laparoscopic lavage and Hart-
mann’s procedure per resource use variable is shown in
Table 4. The cost-driving variables for both base-case
analyses were duration of anaesthesia (mean(s.d.) differ-
ence €–2344(2541), the cost of stoma material in the
12months after index surgery (difference €–2385(2656)),
reoperations (difference €–6253(29 178) and length of
hospital stay for readmissions (difference €1707(9538)).
For base-case B analysis, the difference in mean costs per
treatment group for the sigmoid resection and stoma rever-
sal models were €3670(–) and €18 889(55 045) respectively.
Details of the expected costs for both models are available
in Table S6 (supporting information).
Total mean cost and difference in mean cost per treat-
ment are shown in Table 5. In the base-case A analysis,
mean(s.d.) costs were €18 025(14 646) for laparoscopic
lavage and €27 009(18 445) for Hartmann’s procedure;
the difference was €–8983 (95 per cent c.i. –16 232 to
Table 4 Mean cost per patient per surgical technique and difference in mean cost per resource use variable and surgical technique
Laparoscopic lavage (€) Hartmann’s procedure (€) Difference (lavage – Hartmann’s) (€)
Basic laparoscopic equipment 197 – 197( –)
Surgical instruments 236(20) 231(48) 5(74)
Duration of anaesthesia 3189(1190) 5534(1350) −2344(2541)
Transfusion 39(97) 56(139) −16(243)
Time in recovery room 372(483) 436(478) −64(963)
Length of hospital stay, index operation 5542(3926) 6252(4007) −710(7944)
Antibiotics (infectious adverse events) 65(64) 47(82) 18(146)
Reoperation 5624(10 013) 11 877(17 805) −6253(29 178)
Colonoscopy 435(121) 298(229) 138(354)
Stoma material 199(804) 2584(1672) −2385(2656)
Length of hospital stay, readmission 2571(6196) 864(2797) 1707(9538)
Sigmoid resection model, >12 months*† 3670(1520) – 3670(–)
Stoma reversal model, >12 months*‡ 5763(19 096) 24 652(32 953) −18 889(55 045)
Values are mean(s.d.). *Undiscounted. †No patient in the Hartmann’s group was eligible for sigmoid resection model. ‡Three patients in the laparoscopic
lavage group had a stoma at 12 months and were therefore eligible for the stoma reversal model. For detailed calculations see Tables S1–S3 (supporting
information).
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 1539–1547
on behalf of BJS Society Ltd.
1544 J. Gehrman, E. Angenete, I. Björholt, D. Bock, J. Rosenberg and E. Haglind
Table 5 Mean total cost and difference in mean total cost per surgical technique in different models
Laparoscopic
lavage (€)*
Hartmann’s
procedure (€)*
Difference
(lavage – Hartmann’s) (€) s.d. 95% c.i. P
Base-case A 18 025(14 646) 27 009(18 445) −8983 33 190 −16 232, –1735 0⋅016
Non-parametric bootstrap 32 553 −16 218, –2191 0⋅012
Base-case B 25 703(27 544) 45 498(38 928) −19 794 67 889 −34 657, –4931 0⋅010
Non-parametric bootstrap 66 938 −34 200, –5488 0⋅007
Lin 18 480(14 696) 30 133(17 156) −11653 31 876 −18 614, –4691 0⋅001
Non-parametric bootstrap 31 100 −18 531, –5488 0⋅001
Bang and Tsiatis 18 952(16 681) 29 874(21 166) −10922 37 972 −19 215, –2629 0⋅011
Non-parametric bootstrap 38 007 −19 707, –3256 0⋅009
*Values are mean(s.d.). Non-parametric bootstrap based on 2000 iterations; corresponding confidence intervals are calculated using the value of the 2⋅5
and 97⋅5 per cent percentiles as confidence limits.
–1735; P= 0⋅016). In the base-case B analysis, the costs
were €25 703(27 544) and €45 498(38 928) for laparoscopic
lavage and Hartmann’s procedure respectively, with a
difference in mean total cost of €–19 794 (95 per cent
c.i. –34 657 to –4931). The bootstrap method did not
change the results significantly. Adjusting for censoring in
the base-case A analysis augmented the cost difference in
favour of laparoscopic lavage.
One-way sensitivity analysis was conducted including
the variables that influenced results the most (Table 6).
Robustness was demonstrated for 30 per cent changes in
total costs for duration of anaesthesia, stoma material and
Table 6 Sensitivity analyses
Difference in mean total cost (lavage – Hartmann’s) (€)
Base-case A Base-case B
Sigmoid resection model
Laparoscopic lavage –30% – −20 690 (–35 582, –5799)
Laparoscopic lavage +30% – −18 898 (–33 735, –4061)
Stoma reversal model
Laparoscopic lavage –30% – −21 201 (–35 354, –7049)
Laparoscopic lavage +30% – −18 387 (–33 972, –2802)
Hartmann’s procedure –30% – −14 247 (–27 064, –1431)
Hartmann’s procedure +30% – −25 341 (–42 462, –8219)
Duration of anaesthesia
Laparoscopic lavage –30% −9829 (–17 030, –2628) −20 640 (–35 456, –5824)
Laparoscopic lavage +30% −8138 (–15 436, –839) −18 949 (–33 860, –4037)
Hartmann’s procedure –30% −7531 (–14 746, –315) −18 341 (–33 161, –3522)
Hartmann’s procedure +30% −10 436 (–17 723, –3149) −21 247 (–36 156, –6337)
Length of hospital stay, index operation
Laparoscopic lavage –30% −10 646 (–17 794, –3498) −21 457 (–36 246, –6667)
Laparoscopic lavage +30% −7321 (–14 687, 46) −18 131 (–33 076, –3187)
Hartmann’s procedure –30% −7201 (–14 426, 23) −18 012 (–32 839, –3185)
Hartmann’s procedure +30% −10 765 (–18 057, –3474) −21 576 (–36 486, –6666)
Stoma material
Laparoscopic lavage –30% −9029 (–16 244, –1814) −19 840 (–34 669, –5010)
Laparoscopic lavage +30% −8912 (–16 163, –1661) −19 723 (–34 594, –4852)
Hartmann’s procedure –30% −8218 (–15 428, –1009) −19 029 (–33 789, –4269)
Hartmann’s procedure +30% −9722 (–16 982, –2463) −20 533 (–35 475, –5591)
Length of hospital stay, readmission
Laparoscopic lavage –30% −10 061 (–17 096, –3025) −20 872 (–35 608, –6135)
Laparoscopic lavage +30% −8554 (–15 997, –1111) −19 365 (–34 259, –4471)
Hartmann’s procedure –30% −8951 (–16 168, –1734) −19 762 (–34 584, –4939)
Hartmann’s procedure +30% −9664 (–16 894, –2433) −20 474 (–35 268, –5681)
Reoperation
Laparoscopic lavage –30% −10 670 (–17 591, –3750) −21 481 (–35 974, –6988)
Laparoscopic lavage +30% −7296 (–15 080, 488) −18 107 (–33 220, –2994)
Hartmann’s procedure –30% −5420 (–11 594, 753) −16 231 (–30 239, –2223)
Hartmann’s procedure +30% −12 546 (–21 217, –3876) −23 357 (–39 068, –7646)
Values in parentheses are 95 per cent confidence intervals. Confidence intervals are not based on non-parametric bootstrap.
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 1539–1547
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length of hospital stay for readmission. Changes in the total
cost for length of hospital stay after the index operation
and reoperations affected the results the most. In base-case
B, the results were even more robust and therefore less
sensitive to changes in costs of each variable, as the cost
difference became larger because of the addition of costs
for stoma material and reversal surgery.
In DILALA, laparoscopic lavage was demonstrated
to be more effective and in the present study also less
costly. No cost-effectiveness analysis was warranted
to complete the health economic assessment of the
DILALA study.
Discussion
In this health economic evaluation, laparoscopic lavage as
treatment for perforated diverticulitis with purulent peri-
tonitis resulted in significantly lower costs thanHartmann’s
procedure. These results add an economic perspective to
the demonstrated efficacy and safety of laparoscopic lavage
as treatment for this condition.
There are three other recently published or ongoing
randomized trials comparing laparoscopic lavage with
resection for perforated diverticulitis with purulent peri-
tonitis. None has so far reported economic evaluations.
Two of the other trials9,10 have reported primary endpoints
with no significant differences between laparoscopic
lavage and resection. In the DILALA trial, there was a
lower risk of reoperation for patients undergoing laparo-
scopic lavage, with no significant difference in rate of
adverse events11. The fourth RCT26 has not yet reported
results.
In DILALA, infectious adverse events were observed
more frequently in the laparoscopic lavage group, whereas
serious cardiovascular adverse events were more common
in the Hartmann’s procedure group. The effects of these
adverse events have been included in the costing in the
present study. Similar findings were made within 90 days
in SCANDIV9.
In the DILALA trial, stoma reversal was considered a
reoperation. This is because stoma reversal is associated
with severe morbidity and even death. Thus, from the
patient’s and as well as a health economic point of view,
it is a burdensome procedure. Moreover, successful stoma
reversal could improve health-related quality of life. In
fact, the cost of an uncomplicated stoma reversal corre-
sponds to a few years of cost for stoma material, so it
seems reasonable to strive for stoma reversal whenever
possible.
Many studies of the clinical course after Hartmann’s pro-
cedure for diverticulitis have reported stoma reversal rates
of about 50 per cent within 12 months15. In the DILALA
trial the corresponding figure was 72 per cent11. This was
probably attributed to the trial setting focusing on stoma
reversal more than is usually the case in routine clinical
practice. This makes for a conservative cost estimation for
the Hartmann group in the present cost analysis and there-
fore strengthens the results.
Costs related to long-term stoma care and possible
sigmoid resection beyond the time period of the DILALA
trial were included in the base-case B analysis. The models
addressing these extrapolations include assumptions based
on published data, and the results of the model analyses
are therefore uncertain. Broderick-Villa and co-authors20
analysed treatment for recurrent diverticulitis in a retro-
spective cohort study including 3165 patients with acute
diverticulitis. They found that approximately 13 per cent
of patients had recurrence once or twice after initial
non-operative treatment. Another study27 of 743 patients,
who presented with acute diverticulitis, reported that 242
patients underwent surgery at baseline. During follow-up,
the recurrence rate for these patients was 5⋅8 per cent and
the rate of emergency surgery 1⋅3 per cent. The 25 per
cent rate of sigmoid resection beyond 12 months used in
the base-case B analysis here can be regarded as in favour
of the Hartmann’s procedure group. Furthermore, the
cost difference in base-case B remained robust even when
allowing for 30 per cent changes in expected future costs
for stoma reversal or sigmoid resection.
Stoma use makes the cost of Hartmann’s procedure
increase over time and the difference in costs compared
with laparoscopic lavage is thus expected to grow. This
highlights the importance of including both short- and
long-term costs and consequences in economic evaluations.
This study incorporated potential uncertainties regarding
laparoscopic lavage. Some patients may need sigmoidec-
tomy, as the bowel is not resected in the emergency opera-
tion, and also colonoscopies to make certain that a cancer is
not present. Even with the assumption of a relatively high
probability of resection after the trial, the expected costs of
sigmoidectomy are not comparable to the future expected
costs of a stoma in the Hartmann’s procedure group.
As the cost difference increases after cessation of the
clinical trial, the authors have chosen not to discount future
costs. Results without discounting probably overestimate
the cost to the advantage of laparoscopic lavage. As it is
not known when the events in the model would occur,
discounting would be uncertain. However, the sensitivity
analyses provide a general impression of how discounting
would have affected the results.
In the cost analysis, most variables relating to resource
use were collected prospectively in the setting of a
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randomized trial with long follow-up and few missing
data. Significant differences were found in the majority of
resource use variables8,11. From the sensitivity analyses,
it is concluded that the results are robust to significant
changes in costs.
The study could be criticized for its small cohort size.
However, as the efficacy results, the majority of clinical
resource use variables, and all the calculated costs were
statistically significantly in favour of laparoscopic lavage,
the sample size appears to be sufficient.
Data on productivity loss from paid or unpaid work were
not collected and time in the ICU was not included in the
analysis. Both of these resource use variables may give rise
to rare but extreme costs, which can influence the entire
result of the study and single-handedly tip the result in
one direction, especially if the study contains few patients
as is the case here15. It was reported recently that patients
who underwent open colectomy were absent from work on
average 2⋅75 days more than those who had laparoscopic
surgery28. Based on these results, if sick leave costs were
included, it is likely that Hartmann’s procedure would
be even more costly than laparoscopic lavage. Any future
analysis of a larger cohort should include productivity
losses as well as time in the ICU.
The authors chose to not model incisional hernia in the
base-case B analysis. According to the 5-year results from
the CLASICC (Conventional versus Laparoscopic-Assisted
Surgery in Colorectal Cancer) trial29, 9⋅2 per cent of
patients in the open group experienced hernia compared
with 8⋅6 per cent in the laparoscopic group. In the same
study, 23 of 39 hernias were managed by surgery. However,
as the CLASICC trial included mainly laparoscopic resec-
tions and thus a single incision for removal of the specimen,
it is difficult to translate frequencies directly.
In conclusion, we have shown significant cost reduction
when using laparoscopic lavage compared withHartmann’s
resection as a treatment for perforated diverticulitis with
purulent peritonitis. This and available data on the efficacy
and safety from other randomized trials argue for routine
use of laparoscopic lavage as a treatment in this patient
group.
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